Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Industry News

MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions.

December 16, 2020

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Industry News

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

October 30, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Industry News

First Patients Enrolled in the Gore RELINE MAX Clinical Study

December 15, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Industry News

Boston Heart Reaches Milestone in Statin Intolerance Testing

September 08, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

FDA approves new antiplatelet drug used during heart procedure

June 24, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

Advertisement

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

MagicTouch SCB Granted 'Breakthrough Device Designation' for the treatment of Small Coronary Artery Lesions.

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

First Patients Enrolled in the Gore RELINE MAX Clinical Study

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

Boston Heart Reaches Milestone in Statin Intolerance Testing

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

FDA approves Repatha to treat certain patients with high cholesterol

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

FDA approves new antiplatelet drug used during heart procedure

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content